Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: A modeled analysis

Current Medical Research and Opinion

Volumn 29, Issue 2, 2013, Pages 109-115

  Grima, Daniel T ^a   Dunn, Elizabeth S ^b   Bernard, Lisa M ^a   Mendelssohn, David C ^c  

^a Department of Data Analytics and Evidence Synthesis   (Canada)

^b GENZYME CORPORATION   (United States)

^c HUMBER RIVER REGIONAL HOSPITAL   (Canada)

Author keywords

Calcium based binders; Dialysis; Hospitalization; Hyperphosphatemia; Sevelamer

Indexed keywords

CALCIUM BASED BINDER DERIVATIVE; CALCIUM DERIVATIVE; SEVELAMER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COMPUTER PROGRAM; FEMALE; HEALTH CARE ORGANIZATION; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; HYPERPHOSPHATEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT DURATION; UNITED STATES;

ACETATES; CALCIUM COMPOUNDS; CHELATING AGENTS; CONFIDENCE INTERVALS; FEMALE; HOSPITALIZATION; HUMANS; HYPERPHOSPHATEMIA; MALE; MARKOV CHAINS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; POLYAMINES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84872259951     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.756808     Document Type: Article

References (31)

1. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008;8:117
2. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institute of Health. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2007
3. Afifi A, El-Sayed H, El-Setouhi M, et al. Hyperphosphatemia among end-stage renal disease patients in developing countries: a forgotten issue? Hemodial Int 2005;9:409-15
4. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87
5. Danese MD, Belozeroff V, Smirnakis K, et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1423-9
6. CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113):Sv-vi
7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):S1-202
8. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-30
9. Isakova T, Gutierrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-96
10. Navaneethan SD, Palmer SC, Vecchio M, et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011;2:CD006023
11. St Peter WL, Liu J, Weinhandl E, et al. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;51:445-54
12. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institute of Health. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2008
13. Chan KE, Lazarus JM, Wingard RL, et al. Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge. Kidney Int 2009;76:331-41
14. Brophy DF, Daniel G, Gitlin M, et al. Characterizing hospitalizations of endstage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy. Ann Pharmacother 2010;44:43-9
15. Bhat P, Sokolowski W, Bhat JG. Projected impact of the proposed "bundled" ESRD payment system on a small dialysis organization. Nephrol News Issues 2009;23:46,48-52
16. Siegel J, Jorgenson J, Johnson PE, et al. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings. Am J Health Syst Pharm 2008;65:1711-19
17. Solid CA, Foley RN, Gilbertson DT, et al. Perihospitalization hemoglobinepoetin associations in U.S. hemodialysis patients, 1998 to 2003. Hemodial Int 2007;11:442-7
18. Hutchison CA, Crowe AV, Stevens PE, et al. Case mix, outcome and activity for patients admitted to intensive care units requiring chronic renal dialysis: a secondary analysis of the ICNARC Case Mix Programme Database. Crit Care 2007;11:R50
19. Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-10
20. Yaqub MS, Leiser J, Molitoris BA. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients. Am J Nephrol 2001;21:390-6
21. Medicare Program; End-Stage Renal Disease Quality Incentive Program. 42 CFR Part 413. Department of Health and Human Services. Centers for Medicare & Medicaid Services, 2011
22. United States Renal Data System. An introduction to end-stage renal disease in the United States. In: 2011 Annual Data Report. Am J Kidney Dis 2012;59:147-166
23. London GM, Gué rin AP, Marchais SJ. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrology Dial Transplant 2003;18:1731-40
24. Suki WN. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr 2008;18:91-8
25. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41
26. Collins AJ, St Peter WL, Dalleska FW, et al. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 2000;54:334-41
27. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calciumbased phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7
28. Borzecki AM, Lee A, Wang SW, et al. Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther 2007;32: 617-24
29. Collins AJ, Foley RN, Chavers B, et al. US Renal Data System 2011 Annual Data Report. Am J Kidney Dis 2012;59(suppl 1):e1-e420.
30. Section 1881(h) of the Social Security 2008. Medicare Improvements for Patients and Providers Act (MIPPA). Pub L. 110-275
31. Sullivan J. Bundling and its potential impact on dialysis service providers. Nephrol News Issues 2008;22:12, 14, 16-17